Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials †
By D. Arnold, B. Lueza, J. Douillard, M. Peeters, H. Lenz, A. Venook, V. Heinemann, E. Cutsem, Jean-Pierre Pignon, J. Tabernero and 2 more. Annals of Oncology, 2017
774 citations recorded by the source corpus.
Subfields: Cancer Research, Oncology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/3c7504df89bd6baeb4dd9d1d7acf63dd7a338e55
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pathology and Forensic Medicine
Citations in the corpus
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer (2019, methodology): “Thus, it is recommended that BRAFV600E mutation testing should be performed prior to the administration of first‐line therapy for patients who can receive systemic therapy [219, 220] (CQ‐20).”